













The current WHO classification of haema­
topoietic neoplasms integrates genetic and 
chromosomal aberrations as well as con­
secutive protein changes [2]. Haematopoie­
tic neoplasms are mainly defined morpho­
logically according to their normal coun­
terpart in reactive lymphoid and bone 
marrow tissue. However, many overlap­
ping histological features exist in can­
cerous tissue, making antibody­based 
techniques indispensable to classify lym­
phomas and to increase diagnostic accu­
racy. Immunohistochemistry (IHC) is the 
most important method in routine dia­
gnostics today. Although antibody­based 
methods allow lymphomas to be classi­
fied to a certain extent, there are still ma­
ny “grey zones” with overlapping morpho­
logical and immunophenotypic features, 
making it difficult to determine lympho­
mas exactly [6, 7]. Moreover, among the 
currently available markers used, pro­
gnostic and predictive protein markers are 
still scarce, and the present classification 
seems inadequate in predicting the out­
come of each lymphoma type [3, 4, 5].
The molecular composition and dyna­
mic organization of the plasma membra­
ne (PM) determines how a cell can inter­
act with its environment at any given mo­
ment [9]. The identification of predictive 
and diagnostic PM markers for cancer is 
particularly challenging, because neoplas­
tic cells largely share the same genome and 
proteome as normal cells. Microarray­ 
based mRNA expression profiling experi­
ments can roughly estimate the expressi­
on of a protein by measuring the protein 
encoding mRNA, but they cannot pre­
dict protein localization or post­transla­
tional modifications. In order to under­
stand and unravel cancer biology at the 
molecular level, the PM protein compo­
sition as well as post­ and co­translatio­
nal modifications must be investigated 
directly. Since PM proteins are accessible 
for diagnostic and therapeutic interven­
tion by antibodies or small molecule­ 
based strategies, these protein targets are 
of the greatest interest as potential dia­
gnostic and predictive markers.
Challenges to identifying the PM sub­
proteome arise from the need to overcome 
the technical difficulties in isolating PM 
proteins, the limited relative abundance of 
PM proteins and the difficulty in resolving 
and identifying hydrophobic polypep­
tides. To address these issues, we have de­
veloped new methodologies for the speci­
fic labelling of proteins residing in the PM 
to circumvent the above­mentioned pro­
blems [8]. Our approach exploits the fact 
that most cell surface proteins are glyco­
sylated. Glycosylation of PM proteins is 
a common co­translational modification 
[10]. The highly specific CSC technolo­
















belling strategy to confer the desired spe­
cificity for glycoproteins in the PM sub­
proteomes. Results from model cell lines 
and from primary cells and tissues have 
yielded a degree of specificity never seen 
before in the detection of low­abundance 
PM proteins, with less than 10% contami­
nation from intracellular and non­glyco­
sylated peptides/proteins. The “contami­
nations” can be singled out in a bioinfor­
matics approach, yielding 100% bona fide 
PM proteins. CSC technology uses the 
mass spectrometer as an “antibody” ca­
pable of specifically detecting PM glyco­
proteins that cannot currently be detected 
any other way.
Materials and Methods
Four HL cell lines of nodular sclerosing and 
mixed cellularity type, four diffuse large 
B cell lymphoma (DLBCL) lines of ger­
minal centre and activated cell type and 
a mediastinal B cell lymphoma (MedB1) 
line were investigated via mass spectro­
metry by CSC technology. The cell surface 
proteomes of the cell lines were compared, 
and selected differentially expressed pro­
teins were validated on the single cell le­
vel with affinity­based probes on a forma­
lin­fixed and paraffin­embedded cell line 
array of the same set of cell lines. Valida­
ted protein targets are further analysed on 
newly established lymphoma TMAs from 
patient samples.
Results
A total of 747 predicted transmembrane 
proteins were identified in all cell lines, 
including 142 CD molecules (. Tab. 1). 
Many of the identified proteins are well­
known CD molecules such as CD19, 
CD20 and CD22 in the DLBCL lines or 
CD30 in the HL and MedB1 lines. CSC 
technology also revealed CD molecules 
that are low abundant in lymphoma tis­
sue such as CD2 in the HL lines HDLM2 
and L540. Whereas some of the transmem­
brane proteins are differentially expressed, 
others overlap between different lympho­
ma subtypes (. Fig. 1). Based on all iden­
tified predicted transmembrane proteins, 
unsupervised hierarchical clustering using 
SPOTFIRE software showed a cluster of 
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Immunophenotyping without antibodies.  












































group of HL lines. In contrast, the MedB1 
line was clearly split up with these two 
groups. Though the MedB1 line seems to 
be a distinct entity, it is more closely re­
lated to the HL than to the DLBCL lines. 
Together, the CSC data disclose the cell 
surface proteomes of HL, DLBCL and 
MedB1 lines in great detail and allow for 
novel insights into the functional capaci­
ties of these cells.
Discussion
CSC technology is a mass spectrometry­
based technology that allows for the dis­
covery­driven identification of cell sur­
face proteins regardless of the availability 
of antibodies. The proteomic data genera­
ted correlate with findings from ge­
ne array analysis regarding the related­
ness of Hodgkin’s and mediastinal large 
B cell lymphoma (MedB1) cell lines [3, 
1, 6]. Moreover, the CSC results revealed 
overlapping and differentially expressed 
known and unknown transmembrane 
proteins in the different cell lines. By vali­
dating differentially expressed proteins on 
the investigated cell lines and on primary 
lymphoma tissue, we aim to identify new 
specific markers to facilitate the differen­
tial diagnosis of lymphomas.
As we were recently also able to apply 
the CSC technology to primary tissue, 
























up new perspectives for a refined classifi­
cation of lymphomas and future potential 
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